Navigation Links
Biologics Research Promises to Bolster Future of Medicine

WASHINGTON, March 11, 2013 /PRNewswire-USNewswire/ -- America's biopharmaceutical companies are using biological processes to develop 907 medicines and vaccines targeting more than 100 diseases, according to a new report released today by the Pharmaceutical Research and Manufacturers of America (PhRMA).


The report includes biologics in human clinical trials or under review by the U.S. Food and Drug Administration such as:

  • 338 cancer therapeutics that target several different types of solid tumors, leukemia and lymphoma;
  • 134 vaccines for infectious diseases;
  • 71 medicines for autoimmune diseases including lupus, multiple sclerosis and rheumatoid arthritis;
  • 58 treatments for cardiovascular disease.

"These medicines reflect the cutting-edge research being conducted across the country by biopharmaceutical companies in order to provide new treatment options to patients," stated PhRMA President and CEO John J. Castellani .

The biologic medicines now in development make use of a range of new technologies to harness scientific progress.  Among the biologic medicines in development are:

  • A genetically-modified virus-based vaccine to treat melanoma;
  • A monoclonal antibody for the treatment of asthma;
  • An antisense therapy for the treatment of leukemia;
  • A recombinant fusion protein to treat type 2 diabetes.

"In order to realize the full potential of novel biologics to improve human health, it is essential to maintain public policy and regulatory environments to support the research and development that drives biomedical innovation," concluded Castellani.

The U.S. biopharmaceutical research sector supports nearly four million jobs across the economy, invests billions of dollars in research and development each year, and accounts for nearly 20 percent of all domestic R&D funded by U.S. businesses generating high-quality, high-wage jobs, powering the U.S. economy, and developing critical new treatments against our most costly and challenging diseases. 

The Biologic Medicines in Development report as well as an overview and other supplementary materials are available on PhRMA's website at

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country's leading innovative biopharmaceutical research and biotechnology companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. Since 2000, PhRMA member companies have invested over $500 billion in the search for new treatments and cures, including an estimated $49.5 billion in 2011 alone.

Find PhRMA Online:

For information on how innovative medicines save lives, visit: 
For information on the Partnership for Prescription Assistance, visit:   
For information on ensuring the flow of medicines during public health emergencies, visit

SOURCE Pharmaceutical Research and Manufacturers of America
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Next-Generation Drug-Device Combinations Provide Innovative Delivery Methods for the Growing Biologics Market
2. Synthetic Biologics Reports that Flupirtine Sublicensee, Meda AB, to Initiate Phase II Fibromyalgia Clinical Trial in U.S.
3. Employers Becoming Savvier About Biologics and Specialty Drugs
4. Pinnacle Biologics beantragt Zulassung neuer Indikationen in Deutschland und Frankreich
5. Pinnacle Biologics dépose une nouvelle indication pharmaceutique en Allemagne et en France
6. Pinnacle Biologics acquires PDT laser technology
7. Synthetic Biologics Closes Deal for Acquisition of C. difficile Infectious Disease Program
8. Avaxia Biologics Receives IND Clearance from FDA to Initiate Clinical Program to Evaluate AVX-470 as Therapy for Ulcerative Colitis
9. Cell Culture - Rising Demand for Biologics and Growing Visibility of Approval Pathway for Biosimilars will Create Growth Opportunities
10. Oncobiologics and Boston Oncology Team Up to Deliver Biosimilar Therapies for Cancer and Immune Disease to Middle East and North African Markets
11. Synthetic Biologics Initiates Development of Monoclonal Antibodies for Treatment of Acinetobacter Infections
Post Your Comments:
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the European Cell Surface Marker ... Emerging Opportunities"  report to their offering.  ... announced the addition of the  "2016 ...
(Date:11/25/2015)...  Amgen (NASDAQ: AMGN ) today announced the ... the United States (U.S.) Food and ... to Humira ® (adalimumab). Amgen believes this submission ... FDA and represents Amgen,s first BLA submission using the ... M.D., executive vice president of Research and Development at ...
(Date:11/25/2015)... 25, 2015 AAIPharma Services Corp./Cambridge Major ... at least $15.8  Million to expand its laboratories ... . The expansion will provide additional office ... growing demands of the pharmaceutical and biotechnology markets. ... will provide up to 40,000 square feet of ...
Breaking Medicine Technology:
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... offering factory direct sauna parts and accessories. , Sauna accessories help improve ... the bather’s style and personality. From basic styles for the purist looking for ...
(Date:11/25/2015)... ... November 25, 2015 , ... On November 10, 2015, ... District Court of Connecticut on behalf of a home health care worker who provided ... or former home health care workers employed by Humana, Inc., Humana at Home, Inc., ...
(Date:11/25/2015)... ... November 25, 2015 , ... ... across the country to celebrate their sobriety and show through pictures what a ... and after” photos this Thanksgiving with the hashtag #FacesOfGratitude on their Facebook, Twitter, ...
(Date:11/25/2015)... ... November 25, 2015 , ... Wimbledon Health ... launches new Wimbledon Athletics Facebook page to educate the public, parents ... cardiac abnormalities. About 2,000 people under the age of 25 die from sudden ...
(Date:11/25/2015)... ... November 25, 2015 , ... Smiles by Stevens is ... and moderate facial wrinkling. While many patients are aware of the benefits of Botox® ... Botox® delivers to those suffering with discomfort, soreness, and pain as a result of ...
Breaking Medicine News(10 mins):